Hyperthyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Aug. 10, 2011 - PRLog -- The global hyperthyroidism therapeutics market was valued at $375.0m in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 2.9% to reach $459.0m in 2017. The growth of the market will be slow due to the dominance of generics and the lack of approved drugs. The primary factor driving the market is the increase in the elderly population.

At present, the market is served by therapies such as antithyroid agents (methimazole, propylthiouracil,
carbimazole), radioactive iodine and beta blockers used as an adjuvant therapy. The market is dominated by generics. As the disease can be treated completely, if identified in time, the unmet need is low.

Despite the efficient therapies available for the indication, there are still some unmet needs that can be
tapped by products which could offer better efficacy and safety.

The market for hyperthyroidism therapeutics is strong. Currently, methimazole, carbimazole, propylthiouracil and radioiodine are available in hyperthyroidism therapeutics market. All these drugs are generic and have good efficacy. Although the drugs for hyperthyroidism therapeutics are generics, they efficiently serve the market demand.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

There are four products in the pipeline that are currently in the developmental stages. Three products are in Phase II and one product is in Phase I. The pipeline molecules have better safety and efficacy, as well as novel mechanisms of action. GlaxoSmithKline (GSK) and Genzyme are the key companies with
products in the pipeline.

GlobalData, the industry analysis specialist, has released its new report, “Hyperthyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Hyperthyroidism market. The report identifies the key trends shaping and driving the global Hyperthyroidism market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of
the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hyperthyroidism sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Hype...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.